Concentrations and Credit Risks	9 Months Ended
Sep. 30, 2018
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND CREDIT RISKS	NOTE 9 - CONCENTRATIONS AND CREDIT RISKS Financial instruments that subjected the Company to concentrations of market risk consisted principally of equity investments and debt instruments (other than cash equivalents), which collectively represented approximately 28.2% and 80.4% of the Company’s total assets at September 30, 2018 and December 31, 2017, respectively. These investments consisted of certain securities in companies with no readily determinable market values or in non-public companies, and as such are valued in accordance with the Company’s fair value policies and procedures. The Company’s investment strategy represents a high degree of business and financial risk due to the fact that certain of the Company’s portfolio investments (other than cash equivalents) are generally illiquid, in small and middle market companies, and include entities with little operating history or entities that possess operations in new or developing industries. Investments in non-public entities should they become publicly traded, would generally be (i) subject to restrictions on resale, if they were acquired from the issuer in private placement transactions; and (ii) susceptible to market risk. Additionally, at September 30, 2018, 100% of the fair value of the Company’s equity investment portfolio is concentrated in one company in the biometric technology industry which gives rise to a risk of significant loss should the performance or financial condition of this company or industry deteriorate.

Concentrations and Credit Risks

9 Months Ended

Sep. 30, 2018

NOTE 9 - CONCENTRATIONS AND CREDIT RISKS

Financial instruments that subjected the Company to concentrations of market risk consisted principally of equity investments and debt instruments (other than cash equivalents), which collectively represented approximately 28.2% and 80.4% of the Company’s total assets at September 30, 2018 and December 31, 2017, respectively. These investments consisted of certain securities in companies with no readily determinable market values or in non-public companies, and as such are valued in accordance with the Company’s fair value policies and procedures. The Company’s investment strategy represents a high degree of business and financial risk due to the fact that certain of the Company’s portfolio investments (other than cash equivalents) are generally illiquid, in small and middle market companies, and include entities with little operating history or entities that possess operations in new or developing industries. Investments in non-public entities should they become publicly traded, would generally be (i) subject to restrictions on resale, if they were acquired from the issuer in private placement transactions; and (ii) susceptible to market risk. Additionally, at September 30, 2018, 100% of the fair value of the Company’s equity investment portfolio is concentrated in one company in the biometric technology industry which gives rise to a risk of significant loss should the performance or financial condition of this company or industry deteriorate.